Article source: https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-older-adults-92-protective-against-poor-outcomes-real

The provided text, originating from the University of Minnesota's Center for Infectious Disease Research & Policy (CIDRAP), primarily offers an overview of a real-world study estimating the effectiveness of the RSVpreF (Abrysvo) vaccine in adults aged 60 and older.

The study found the vaccine to be 92% effective against severe outcomes like emergency department visits or hospitalizations for respiratory illness, with effectiveness rising to 95% in those aged 75 and older.

It notes that this level of protection is higher than other current respiratory vaccines and suggests continued evaluation is needed, especially with pending recommendations for younger adults; however, it also reports that the uptake of the vaccine has been low.

Additionally, the source includes a section on related infectious disease news and information about CIDRAP, including its underwriters and contact details.